LZAGF - Lonza Group AG
Lonza Group AG
Muenchensteinerstrasse 38
Basel 4002
Switzerland
41 61 316 81 11
https://www.lonza.com
Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 17,494
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Dr. Pierre-Alain Ruffieux Ph.D. | Chief Exec. Officer | 2.4M | N/A | 1969 |
| Mr. Philippe Deecke | Chief Financial Officer | N/A | N/A | 1972 |
| Ms. Maria Soler Nunez | Head of Group Operations | N/A | N/A | 1969 |
| Mr. Dirk Oehlers | VP of Investor Relations | N/A | N/A | N/A |
| Mr. Andreas Bohrer | Group Gen. Counsel & Company Sec. | N/A | N/A | N/A |
| Ms. Victoria Morgan | Head of External Communications | N/A | N/A | N/A |
| Ms. Jennifer Clancy | Sr. Director of Global Marketing | N/A | N/A | N/A |
| Dr. Matthias Hofmann | Head of Corp. Environment, Health, Safety & Global Sustainability | N/A | N/A | N/A |
| Mr. Jean-Christophe Hyvert | Pres of Biologics Division | N/A | N/A | 1972 |
| Ms. Aurelie Dalbiez | Head of Strategic HR Projects | N/A | N/A | 1977 |
Description
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was incorporated in 1897 and is headquartered in Basel, Switzerland.
Corporate governance
Lonza Group AG’s ISS governance QualityScore as of 1 June 2023 is 1. The pillar scores are Audit: 4; Board: 1; Shareholder rights: 1; Compensation: 2.
